Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Melanoma: Clinical Trials and Translational Research
share announcement

Melanoma: Clinical Trials and Translational Research

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".

Deadline for manuscript submissions: 30 May 2025 | Viewed by 2387

Special Issue Editors

Dr. Roberta Giuffrida

E-Mail Website
Guest Editor
Department of Clinical and Experimental Medicine, University of Messina, 98124 Messina, Italy
Interests: dermato-oncology; melanoma; non-melanoma skin cancer; signaling pathways; targeted therapy; artificial intelligence; noninvasive skin imaging; autoimmune/autoinflammatory skin diseases
Special Issues, Collections and Topics in MDPI journals
Dr. Claudio Guarneri

E-Mail Website
Guest Editor
Department of Biomedical and Dental Sciences and Morpho Functional Imaging, University of Messina, Messina, Italy
Interests: Melanoma; Clinical Dermatology; Psoriasis; Treatment; Skin; Cosmetic Surgery; Pathogens; Infection; Diagnosis; Biomarkers; Targeted Therapy; Autoimmune/Autoinflammatory Skin Disease
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Linda Tognetti

E-Mail Website
Guest Editor
Dermatology Unit, Department of Medical, Surgical and Neurosciences, University of Siena, Siena, Italy
Interests: dermato-oncology; melanoma; non-melanoma skin cancer; noninvasive skin imaging; artificial intelligence; pediatric dermatology; translational dermo-research; photobiology
Special Issues, Collections and Topics in MDPI journals
Dr. Claudio Conforti

E-Mail Website
Guest Editor
Dermatology Clinic of Trieste, Maggiore Hospital, University of Trieste, Trieste, Italy
Interests: dermato-oncology; general dermatology; melanoma; non-melanoma skin cancer; targeted therapy; immunotherapy; noninvasive skin imaging; aesthetic medicine; dermatologic surgery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Melanoma is the deadliest type of skin cancer. It arises from melanocytes in skin, mucous membranes, eyes, or the central nervous system, following genetic, epigenetic and allogenetic alterations, and has the potential to spread to any organ of the body. Generally, this tumor can be cured, if diagnosed in the early stages, with high survival rates. However, patients with advanced disease have a poor prognosis.

In the past two decades, much progress has been made in the diagnosis and treatment of melanoma, also thanks to the increased knowledge of tumor biology, which has led to a targeted approach and personalized melanoma therapeutic strategies.

The aim of this Special Issue is to publish innovative and high quality original/review articles focused on the development and improvement of new ways to prevent, diagnose, and treat melanoma by translating findings observed in a laboratory into clinical applications.

We look forward to receiving your contributions.

Dr. Roberta Giuffrida
Dr. Claudio Guarneri
Prof. Dr. Linda Tognetti
Dr. Claudio Conforti
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • melanoma
  • skin cancer
  • biomarkers
  • genomics
  • diagnosis
  • therapy
  • immunotherapy
  • targeted therapy
  • resistance

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

9 pages, 1208 KiB  
Article
Real-World Cardiotoxicity in Metastatic Melanoma Patients Treated with Encorafenib and Binimetinib
by Sidsel Pedersen, Marc Østergaard Nielsen, Marco Donia, Inge Marie Svane, Bo Zerahn and Eva Ellebaek
Cancers 2024, 16(17), 2945; https://doi.org/10.3390/cancers16172945 - 23 Aug 2024
Cited by 1 | Viewed by 772
Abstract
Modern therapies targeting the BRAF gene mutation in advanced melanoma have significantly improved patient outcomes but pose cardiovascular risks. This retrospective study in Eastern Denmark (2019–2022) assessed 108 melanoma patients treated with encorafenib and binimetinib. Patients were monitored for heart function using multigated [...] Read more.
Modern therapies targeting the BRAF gene mutation in advanced melanoma have significantly improved patient outcomes but pose cardiovascular risks. This retrospective study in Eastern Denmark (2019–2022) assessed 108 melanoma patients treated with encorafenib and binimetinib. Patients were monitored for heart function using multigated acquisition (MUGA) scans. The study defined major cardiotoxicity as a decline in left ventricular ejection fraction (LVEF) by more than 10 percentage points to below 50%, and minor cardiotoxicity as a decrease in LVEF by more than 15 points but remaining above 50%. Results showed that 19 patients (18%) developed minor cardiotoxicity and were asymptomatic, while 7 (6%) experienced major cardiotoxicity, with two requiring intervention. Notably, no significant declines in LVEF were observed after six months of treatment. The study concluded that significant cardiotoxicity occurred in 6% of cases, mostly asymptomatic and reversible, and suggests that monitoring LVEF could potentially be reduced after 6–9 months if no early signs of cardiotoxicity are detected. This provides valuable insights into the cardiac safety of these treatments in real-world settings. Full article
(This article belongs to the Special Issue Melanoma: Clinical Trials and Translational Research)
►▼ Show Figures

Figure 1

17 pages, 5626 KiB  
Article
Association of miR-146a-5p and miR-21-5p with Prognostic Features in Melanomas
by Maria Naddeo, Elisabetta Broseghini, Federico Venturi, Sabina Vaccari, Barbara Corti, Martina Lambertini, Costantino Ricci, Beatrice Fontana, Giorgio Durante, Milena Pariali, Biagio Scotti, Giulia Milani, Elena Campione, Manuela Ferracin and Emi Dika
Cancers 2024, 16(9), 1688; https://doi.org/10.3390/cancers16091688 - 26 Apr 2024
Viewed by 1248
Abstract
Background: Cutaneous melanoma (CM) is one of the most lethal tumors among skin cancers and its incidence is rising worldwide. Recent data support the role of microRNAs (miRNAs) in melanoma carcinogenesis and their potential use as disease biomarkers. Methods: We quantified the expression [...] Read more.
Background: Cutaneous melanoma (CM) is one of the most lethal tumors among skin cancers and its incidence is rising worldwide. Recent data support the role of microRNAs (miRNAs) in melanoma carcinogenesis and their potential use as disease biomarkers. Methods: We quantified the expression of miR-146a-5p and miR-21-5p in 170 formalin-fixed paraffin embedded (FFPE) samples of CM, namely 116 superficial spreading melanoma (SSM), 26 nodular melanoma (NM), and 28 lentigo maligna melanoma (LMM). We correlated miRNA expression with specific histopathologic features including Breslow thickness (BT), histological subtype, ulceration and regression status, and mitotic index. Results: miR-146a-5p and miR-21-5p were significantly higher in NM compared to SSM and LMM. The positive correlation between miR-146a-5p and miR-21-5p expression and BT was confirmed for both miRNAs in SSM. Considering the ulceration status, we assessed that individual miR-21-5p expression was significantly higher in ulcerated CMs. The increased combined expression of the two miRNAs was strongly associated with ulceration (p = 0.0093) and higher mitotic rate (≥1/mm2) (p = 0.0005). We demonstrated that the combination of two-miRNA expression and prognostic features (BT and ulceration) can better differentiate cutaneous melanoma prognostic groups, considering overall survival and time-to-relapse clinical outcomes. Specifically, miRNA expression can further stratify prognostic groups among patients with BT ≥ 0.8 mm but without ulceration. Our findings provide further insights into the characterization of CM with specific prognostic features. The graphical abstract was created with BioRender.com. Full article
(This article belongs to the Special Issue Melanoma: Clinical Trials and Translational Research)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop